Impact of GLP-1 Receptor Agonists on Patients With IPMN

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

IPMNIPMN, PancreaticGLP-1Intraductal Papillary Mucinous Neoplasm of PancreasGlucagon-Like Peptide-1 Receptor Agonists

Interventions

DRUG

GLP1 receptor agonist

Patients must be under GLP1-RA treatment for ether diabetes or obesity

Trial Locations (1)

HFR Hopital fribourgeois, Villars-sur-Glâne

All Listed Sponsors

collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

collaborator

University Hospital, Geneva

OTHER

lead

Hôpital Fribourgeois

OTHER

NCT07014709 - Impact of GLP-1 Receptor Agonists on Patients With IPMN | Biotech Hunter | Biotech Hunter